<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="17698">Chloramphenicol</z:chebi>-induced <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> is well described in the literature following oral use of the drug </plain></SENT>
<SENT sid="1" pm="."><plain>Here we describe the first case we are aware of in which <z:chebi fb="0" ids="17698">chloramphenicol</z:chebi> eye ointment resulted in severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> and, subsequently, <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>At least two cases of marrow <z:mpath ids='MPATH_133'>hypoplasia</z:mpath> following use of <z:chebi fb="0" ids="17698">chloramphenicol</z:chebi> eyedrops have been described previously in the literature </plain></SENT>
<SENT sid="3" pm="."><plain>The absorption route, its possible relation to the pathogenesis of <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, and the two types of marrow toxicity associated with <z:chebi fb="0" ids="17698">chloramphenicol</z:chebi> are reviewed </plain></SENT>
<SENT sid="4" pm="."><plain>This case emphasizes the necessity for the same careful consideration for the use of topical preparations that one affords the use of parenterally and orally administered medications </plain></SENT>
</text></document>